BACKGROUND With the introduction of novel monoclonal antibody products into the clinic, significant new strategies are being developed to improve upon existing treatment for non-Hodgkin's lymphoma. METHODS Monoclonal antibodies are being used alone, in combination with chemotherapy, or as adjuncts to autologous bone marrow transplantation for the purpose of purging bone marrow of neoplastic c...

background: burkitt lymphoma is a common subtype of non-hodgkin lymphoma in children. it has a rapid and aggressive clinical course with frequent involvement of bone marrow and central nervous system. systemic chemotherapy is the mainstay of the treatment for this malignancy in children. in this systematic review, we discuss autologous and allogeneic hematopoietic stem cell transplantation (hsc...

By H. S. WINCHELL, MYRON POLLYCOVE, W. D. LOUGHMAN AND J. H. LAWRENCE R ELATIVELY selective beta irradiation of the lymphatic system in the dog has been achieved with internally administered Yttrium90 chelated with diethylene triamine penta-acetic acid ( Y90-DTPA) . Intravenous injection of Y#{176}#{176}-DTPA followed by continuous intravenous infusion of the animal’s own urine containing the e...

By H. S. WINCHELL, MYRON POLLYCOVE, W. D. LOUGHMAN AND J. H. LAWRENCE R ELATIVELY selective beta irradiation of the lymphatic system in the dog has been achieved with internally administered Yttrium90 chelated with diethylene triamine penta-acetic acid ( Y90-DTPA) . Intravenous injection of Y#{176}#{176}-DTPA followed by continuous intravenous infusion of the animal’s own urine containing the e...

Patients with solid tumors are increasingly being treated by autologous bone marrow transplantation (BMT). Although response rates appear to be increased, disease recurrence is the commonest cause of treatment failure. Whether relapse is entirely due to residual disease in the patient or arises also from infiltrating malignant cells contained in the autologous marrow transplant has not been res...

Relapse after autologous bone marrow transplantation for chronic myelogenous leukemia (CML) can be due either to the persistence of leukemia cells in systemic tissues following preparative therapy, or due to the persistence of leukemia cells in the autologous marrow used to restore marrow function after intensive therapy. To help distinguish between these two possible causes of relapse, we used...

Graft-versus-host disease (GVHD) remains a major complication of bone marrow transplantation. This report describes reversal of GVHD by infusion of stored recipient bone marrow following combined liver-bone marrow allotransplantation. Graft-versus-host disease developed at the end of the first postoperative week. The skin involvement progressively spread to approximately 80% of the body surface...

background: bone marrow-derived mesenchymal cellscan transdifferentiate into cardiomyocyte cells and improveheart function after transplantation. since biomaterials canimprove the cell retention in the site, cell survival and differentiation,heart tissue engineering is now being explored as anapplied solution to support cell-based therapies and increasetheir efficacy for myocardial diseases. ch...

In the bone marrow, there are certain populations of stem cell sources with the capacity to differentiate into several different types of cells. Ideally, cell transplants would be readily obtainable, easy to expand and bank, and capable of surviving for sufficient periods of time. Bone marrow mesenchymal stem cells (BM-MSCs) possess all of these characteristics. One of the most important benefi...

©F err at S tor ti F ou nd ati o ling donor myeloablative transplantation conducted in the mid-1990s favored the allogeneic bone marrow strategy because of a lower probability of relapse, despite the high incidence of treatment-related mortality of up to 30%. In all of the prospective studies, and in general during this period, autotransplants were performed with a bone marrow graft and led to ...